Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Email

Bevacizumab (AVASTIN®)

Agent Description

A monoclonal antibody biologic that inhibits tumoral angiogenesis to suppress tumor growth.

Mechanism of Action

Anti-angiogenesis inhibitor.

Classification

Anti-angiogenesis inhibitor, anticancer agent, monoclonal antibody.

Molecular Target

VEGF

Monograph

Approved in the US for colorectal cancer, NSCLC, RCC, GBM, ovarian cancer, cervical cancer.

View the bevacizumab package insert (PDF).

Studies of Interest

Combinations with immunotherapeutic agents.

Information collaborator would like included in investigator proposals

N/A

Genentech supports non-clinical research proposals through a separate mechanism. Please visit Genentech's Outgoing Material Transfer Agreement (MTA) Program to submit a request for a Genentech agent for non-clinical work.

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Bevacizumab (AVASTIN®) was originally published by the National Cancer Institute.”

Email